✦ LIBER ✦

Longevity in Parkinson's disease treated with L-DOPA

✍ Scribed by Birkmayer, W.; Ambrozi, L.; Neumayer, E.; Riederer, P.

Book ID: 122698710
Publisher: Elsevier Science
Year: 1974
Tongue: English
Weight: 170 KB
Volume: 77
Category: Article
ISSN: 0303-8467
DOI: 10.1016/S0303-8467(74)80015-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impaired transmethylation potential in P

Impaired transmethylation potential in Parkinson's disease patients treated with l-Dopa

✍ Maria Luigia De Bonis; Alessandro Tessitore; Maria Teresa Pellecchia; Katia Long 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 276 KB

L-DOPA TREATMENT IN PARKINSON'S DISEASE

✍ U. K. Rinne; V. Sonninen; T. Siirtola 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

L-dopa's action in parkinson's disease

✍ C.D. Marsden; P. Jenner 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 436 KB

Plasma homocysteine levels in L-dopa-tre

Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions

✍ Zoccolella, Stefano; Lamberti, Paolo; Iliceto, Giovanni; Diroma, Cosimo; Armenis 📂 Article 📅 2005 🏛 Walter de Gruyter GmbH & Co. KG 🌐 English ⚖ 73 KB

Dementia and treatment with L-dopa in Pa

Dementia and treatment with L-dopa in Parkinson's disease

✍ M. Hietanen; Dr. H. Teräväinen 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

We compared the neuropsychological performance of patients with Parkinson's disease who were young at onset of the disease (mean age, 41.4 years) and had received prolonged L-dopa treatment (mean, 52.1 months) with nontreated patients of the same age. A similar comparison was made for patients who w

Simultaneous MAO-B and COMT inhibition i

Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with parkinson's disease

✍ Dr. Jukka Lyytinen; Seppo Kaakkola; Sirpa Ahtila; Päivi Tuomainen; Heikki Terävä 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 801 KB

## Abstract The effect of selegiline (L‐deprenyl) on plasma catecholamines, clinical response, and drug tolerability was studied in 13 patients with Parkinson's disease (PD) treated with L‐Dopa/benserazide and entacapone, a peripheral catechol‐__O__‐methyltransferase (COMT) inhibitor, in a placebo‐